CLINICAL TRIALS PROFILE FOR OCALIVA

All Clinical Trials for OCALIVA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04939051 ↗	Obeticholic Acid for Prevention in Barrett's Esophagus	Not yet recruiting	National Cancer Institute (NCI)	Phase 2	2021-12-08	This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid, may help increase bile flow from the liver while suppressing bile acid production, therefore reducing the exposure of the liver to toxic levels of bile acids which is potentially linked to cancer development.
NCT05112822 ↗	Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)	Not yet recruiting	M.D. Anderson Cancer Center	Phase 1	2022-03-31	This is a trial that intends to evaluate the effect of treatment with the drug obeticholic acid in the treatment of the Familial Adenomatous Polyposis condition.
NCT05223036 ↗	Testing Obeticholic Acid for Familial Adenomatous Polyposis	Not yet recruiting	National Cancer Institute (NCI)	Phase 2	2022-07-11	This phase IIa trial investigates if giving obeticholic acid (OCA) has an effect on the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is a rare gene defect that increases the risk of developing cancer of the intestines and colon. OCA is a drug similar to bile acids, a fluid made and released by the liver. It binds to a receptor in the intestine that is believed to have a positive effect on preventing cancer development. OCA has been effective in treating primary biliary cholangitis (PBC), a liver disease, and is approved by the Food and Drug Administration (FDA). There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.

Clinical Trial Conditions for OCALIVA

Condition Name

Condition Name for OCALIVA
Intervention	Trials
Familial Adenomatous Polyposis	2
Attenuated Familial Adenomatous Polyposis	1
Barrett Esophagus	1

Condition MeSH

Condition MeSH for OCALIVA
Intervention	Trials
Nasopharyngeal Neoplasms	2
Colorectal Neoplasms	2
Adenomatous Polyposis Coli	2

Clinical Trial Locations for OCALIVA

Trials by Country

Trials by Country for OCALIVA
Location	Trials
United States	5
Puerto Rico	1
China	1
Belgium	1

Trials by US State

Trials by US State for OCALIVA
Location	Trials
Texas	1
Ohio	1
Michigan	1
Massachusetts	1
Arizona	1

Clinical Trial Progress for OCALIVA

Clinical Trial Phase

Clinical Trial Phase for OCALIVA
Clinical Trial Phase	Trials
PHASE3	1
Phase 2	2
Phase 1	1

Clinical Trial Status

Clinical Trial Status for OCALIVA
Clinical Trial Phase	Trials
Not yet recruiting	3
COMPLETED	1
Recruiting	1

Clinical Trial Sponsors for OCALIVA

Sponsor Name

Sponsor Name for OCALIVA
Sponsor	Trials
National Cancer Institute (NCI)	2
M.D. Anderson Cancer Center	1
Intercept Pharmaceuticals	1

Sponsor Type

Sponsor Type for OCALIVA
Sponsor	Trials
NIH	2
Other	2
Industry	2

Ocaliva (obeticholic acid) clinical trials update, market analysis, and revenue projection (2025-2035)

Last updated: August 1, 2026

Ocaliva (obeticholic acid, OCA) remains a niche, high-efficacy option in advanced primary biliary cholangitis (PBC) and is also positioned in noncirrhotic nonalcoholic steatohepatitis (NASH/NASH-related fibrosis) where uptake is constrained by evolving standards of care and payer restrictions. The near-term market is driven by PBC label breadth and tolerability, while medium-term upside depends on (1) commercial execution in PBC, (2) successful repositioning in NASH subsets, and (3) competitors gaining or losing share as guideline recommendations evolve.

What is Ocaliva (obeticholic acid) approved for and what is the current FDA label status?

Executive snapshot (label scope):

• Indication 1 (PBC): Ocaliva is approved for PBC in adults:
  • With inadequate response to ursodeoxycholic acid (UDCA), or
  • As monotherapy in adults unable to tolerate UDCA.
• Indication 2 (PBC, combination): Used in combination with UDCA where applicable (per label structure for inadequate response).
• Safety constraint: Dose adjustments are required for hepatic impairment. Caution applies in patients with decompensated cirrhosis (label-driven).
• Other indications: Ocaliva has had NASH/NASH-related development and label activity in the past; the presence and scope of any active FDA indication should be confirmed against the latest FDA label text.

Regulatory pathway context:

• Ocaliva’s PBC approvals were supported by clinical endpoints in surrogate and clinically meaningful biomarkers (notably ALP and bilirubin) that translate to accepted risk endpoints in PBC.

Commercial implication:

• PBC patients are a relatively stable, chronic population, creating a durable baseline. Uptake depends on endocrinology-gastroenterology referral patterns, UDCA failure rate recognition, and insurer coverage criteria (especially around pruritus management and dosing in hepatic impairment).

What clinical trials update exists for Ocaliva in PBC since major pivotal studies?

Executive answer:

• Post-approval activity in Ocaliva has largely shifted toward label refinement, safety in broader real-world populations, dose optimization, and comparative positioning rather than standalone late-stage pivotal readouts.
• The highest-impact future trial signals for market expansion are most likely to come from NASH fibrosis stratification and combination regimens rather than incremental PBC biomarker trials.

Which PBC endpoints matter most for continued Ocaliva differentiation?

• ALP normalization and bilirubin changes in appropriate subgroups
• Pruritus burden and tolerability across dosing changes
• Progression to cirrhosis-related outcomes where data exist or are being modeled
• Long-term survival linkage as postmarketing evidence matures

How do safety events affect patient retention and prescribing patterns?

• Pruritus is the key tolerability limiter.
• In practice, tolerability determines:
  • persistence in therapy,
  • dose reductions or interruptions,
  • switching to alternative agents in PBC.

What clinical trials update exists for Ocaliva in NASH/NASH-related fibrosis?

Executive answer:

• Ocaliva’s NASH story is not purely about efficacy. It is about whether OCA can secure a payer-acceptable niche in the rapidly changing NASH landscape dominated by agents targeting key metabolic and inflammatory pathways.
• The market outcome depends on whether OCA can demonstrate competitive response rates, acceptable tolerability, and a clear place in guideline algorithms (often as part of combination strategies).

What NASH trial design factors determine whether Ocaliva can win market share?

• Fibrosis stage inclusion (F2 to F3 vs F3 to F4 emphasis)
• Composite endpoints (biopsy-based and imaging surrogates)
• Subgroup effects (diabetes status, obesity phenotype, baseline fibrosis)
• Combination background therapy tolerance and additive benefit

How do OCA’s mechanism and tolerability map to NASH payer decisions?

• OCA’s mechanism in bile acid signaling can be meaningful where cholestatic and metabolic-liver pathways overlap.
• Payers generally require either:
  • strong histologic endpoints in relevant fibrosis strata, or
  • a clearly differentiated benefit with manageable adverse events.

What is the current Ocaliva market size in PBC and what drives demand?

Executive snapshot (demand drivers):

• Patient pool: adults with PBC who fail UDCA or cannot tolerate UDCA.
• Therapy depth: Ocaliva is positioned after UDCA failure. This creates a “conversion” dynamic where diagnosis and UDCA management quality affect OCA demand.
• Tolerability: pruritus management impacts persistence and switching.
• Regional coverage: formularies and step edits strongly influence net uptake.

Key commercial drivers

• Gastroenterology prescribing access: hepatology and GI centers adopt earlier due to the PBC specialty flow.
• Treatment targets: ALP and bilirubin response targets align with clinician comfort for dose and management strategies.
• Payer friction: coverage can restrict dosing, pruritus management, and hepatic impairment cohorts.

How strong is Ocaliva’s competitive position in PBC versus alternative therapies?

Executive answer:

• Ocaliva’s PBC differentiation remains efficacy in UDCA inadequate responders with a relatively distinct mechanism from standard therapy.
• Competitive pressure comes from:
  • other bile-acid and metabolic modulators where available,
  • emerging PBC-specific pipeline assets,
  • off-label use and supportive management pathways.

What determines share retention in PBC?

• Sustained response in ALP/bilirubin targets.
• Pruritus mitigation strategies that preserve adherence.
• Physician comfort with dosing in hepatic impairment.

When does Ocaliva lose exclusivity and what generic entry risks exist?

Executive answer:

• Ocaliva’s exclusivity and generic entry risk depend on the timing of:
  • composition-of-matter and formulation patent expirations,
  • method-of-use patent expirations (especially for PBC dosing regimens),
  • any regulatory exclusivities tied to approvals.
• Generic entry is typically triggered by ANDA filings with Paragraph IV certifications or by expiration of applicable exclusivities.

How does patent expiration translate into launch timing?

• If patents expire after a given year, generic approval can still occur earlier but market entry often requires:
  • patent resolution,
  • a settlement that changes launch dates,
  • or expiration of remaining stay triggers.

What patents protect Ocaliva and how many Orange Book listings typically cover the product?

Executive answer:

• Ocaliva’s patent estate typically spans:
  • composition claims for obeticholic acid and related salts/solid forms,
  • formulation and dose-formulation claims (including delivery characteristics),
  • method-of-use claims tied to PBC or specific patient selection.
• A full Orange Book mapping is required to count exact listings and expiration dates, and to identify which are Orange Book “blocking” patents for generic entry.

Has any Ocaliva Paragraph IV challenge or generic litigation occurred?

Executive answer:

• Generic litigation outcomes materially affect market projections, including launch dates and settlement-for-payment terms.
• Paragraph IV outcomes can shift the effective market exclusivity period by years even when some patents are expiring.

What is the Orange Book status of Ocaliva and which patents are most likely to block generics?

Executive answer:

• The blocking patents are typically the latest-expiring method-of-use and formulation listings that are directly asserted against ANDA filers.
• Determining “blocking” requires:
  • list-by-list mapping of Orange Book patents to ANDA certification events,
  • and confirmation of which patents were asserted and stayed.

What FDA safety communications and label restrictions affect Ocaliva use and demand?

Executive answer:

• The product’s positioning is constrained by hepatic safety considerations. Clinicians manage:
  • baseline bilirubin/INR and liver impairment severity,
  • dose reductions and contraindication-like caution thresholds,
  • monitoring and discontinuation in decompensation risk.

How do hepatic impairment restrictions change TAM?

• Patients with advanced decompensated disease reduce eligible TAM even if they have PBC.
• This lowers addressable uptake versus a broader PBC target definition.

How does Ocaliva compare with competitors in dosing, efficacy, and tolerability in PBC?

Executive answer:

• OCA differentiates through biochemical response in UDCA inadequate responders.
• Competitors can win by:
  • better tolerability,
  • easier dosing in hepatic impairment,
  • stronger or more durable patient-reported outcomes (itch, fatigue).

What is the revenue projection for Ocaliva through 2030 under multiple market scenarios?

Executive answer:

• Ocaliva revenue trajectory is best modeled as a base-case driven by PBC chronic therapy with upside/downside from NASH probability-weighted commercialization.
• Without exact current-year revenue baselines and latest IQVIA/industry estimates, projections can only be expressed as scenario frameworks rather than precise dollar forecasts.

Scenario framework (decision-grade assumptions)

• Base case (PBC focus, limited NASH traction):
  • PBC maintains steady share among UDCA inadequate responders.
  • NASH efforts do not materially expand addressable market before 2030.
• Bull case (PBC steady plus NASH subset wins):
  • NASH trials show histologic benefit in a payer-approved subgroup.
  • Combination-friendly positioning reduces tolerability friction.
• Bear case (PBC share pressure and adverse access):
  • Formulary restrictions tighten due to pruritus management cost or hepatic safety concerns.
  • Competitive therapies in PBC gain share, reducing incremental uptake.

Projection method

• Start with PBC treated-prevalence and therapy persistence.
• Apply market share and incidence conversion assumptions tied to diagnosis/UDCA treatment patterns.
• Add NASH probability-weighted revenue only if a pathway to guideline placement exists (trial success plus payer adoption).

What commercialization risks could cap Ocaliva growth?

Executive answer:

• Ocaliva growth is capped by:
  • tolerability-driven switching in PBC,
  • hepatic impairment usage constraints,
  • payer step therapy,
  • and competitive NASH dynamics if OCA fails to secure a distinct value proposition.

Key Takeaways

• Ocaliva’s commercial foundation is PBC in adults with inadequate response to UDCA or inability to tolerate UDCA.
• Demand is stable but sensitive to pruritus management, hepatic safety constraints, and payer coverage.
• NASH upside exists only if OCA can secure competitive histologic efficacy and a guideline-accepted role in a crowded therapeutic landscape.
• Patent and Orange Book status determine generic entry risk; the effective exclusivity timeline depends on which “blocking” listings and stays apply.

FAQs

1. What biomarkers best predict Ocaliva response persistence in PBC (ALP, bilirubin)?
2. How do hepatic impairment dose restrictions reduce eligible PBC patient pool for Ocaliva?
3. Which NASH patient subsets would most likely benefit from obeticholic acid based on trial design patterns?
4. What Orange Book patent categories (composition, formulation, method-of-use) most often block ANDA launches for specialty hepatology drugs?
5. How does Paragraph IV litigation timing typically affect realistic generic market entry for branded liver drugs?

References

1. FDA. Ocaliva (obeticholic acid) prescribing information and FDA labeling. (Current FDA label).
2. FDA. Drug Approval Packages and approval history for Ocaliva (obeticholic acid). FDA.
3. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Ocaliva listings). FDA.